Phase 2 study for people with Kidney Cancer

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Pfizer
Registry number NCT07227415
Started 10 February 2026 Today 16 October 2026 Estimated completion 2 November 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Icon Cancer Centre Wesley Auchenflower QLD Recruiting
Monash Health Clayton VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 224

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* 18 years of age or older at screening

* Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC with diagnosis confirmed by histology/cytology

* At least one measurable (as defined by the investigator) and untreated lesion

* Adequate hematologic, hepatic, cardiac and renal function

* No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received \>12 months prior)

* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

* All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based risk categories

Exclusion Criteria:

Participants may be excluded if they meet any of the following:

* Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression.

* Clinically significant risk of haemorrhage or fistula

* History of another malignancy within 3 years

* History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.

* active autoimmune diseases requiring systemic treatment within the past 2 years

* uncontrolled cardiac and other comorbidities within 6 months prior to the first dose

* Major surgery or severe trauma within 4 weeks before the first dose, or planned major surgery during the study

* History of severe bleeding tendency or coagulation dysfunction

* History of oesophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months prior to the first dose

* Acute, chronic or symptomatic infections

* Participants with history of immunodeficiency

Dates on the record

Started 10 February 2026
Estimated completion 2 November 2027
Registry last updated 8 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 8 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.